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eventually found to have large mediastinal lymphadeopathy 1 (LAP). It was followed by a dozen additional patients who 2 were largely asymptomatic, but had mediastinal masses. This disorder is also known as angiofollicular lymph node hyperplasia, giant lymph node hyperplasia, lymphoid hamartoma and benign lymphoma or follicular 3 lymphoreticuloma. HPE revealed increased number of lymphoid follicles. Germinal canters varied in their cellularity, ranging from acellular fibrinous hyalinization of capillaries to proliferation of pale eosinophilic cells with copious cytoplasm. In subsequent years, additional cases of patients with diffuse LAP and the histologically characteristic 4 CD lymph node architecture were identified. These series also revealed a new verdict of CD, the germinal centres in the involved nodes showed no evidence of hyalinization, but were normal. Right thoracotomy revealed multiple lymph nodes around right hilum. 
Discussion
Fifty years ago, Dr. Benjamin Castleman described this rare lymphproliferative disorder and was named as Castleman's disease after him. He initially described a patient who presented with many years of fever and weakness, were surrounded by concentric sheets of plasma cells in the 5 inter follicular space. This novel histologic variant was termed 'plasma cell variant (PCV-CD). The recognition of both patients with localized LAP and disseminated disease led to an additional clinical categorization of CD: 'Unicenteric(UCD) versus "multicentric" (MCD). More, recently a third 'sub variant' known as 'plasmablastic MCD' has been described in association with particularly aggressive cases of MCD. In such first series CD patients with POEMS syndrome (Polyneuropathy, organomegaly, endocrinopathy, monoclonal proteins, skin changes) were found to have lymph nodes which resembled PCV, but also had large plasma cells in mantle zone with copious cytoplasm and prominent single or multiple nucleoli, second series found it associated with HHV-8 infection and progression to plasma 6, 7, 8 blastic lymphoma. The initial step in the development CD appears to be production of IL-6 by B-cells in the lymph node mantle zone, stimulated in the majority of cases by HHV-8 infection and in a minority of cases by a heretofore unidentified exogenous or endogenous factor. Local elaboration of IL-6, and in turn VEGF, produces the characteristic B-cell proliferation and vascularization of CD. In patients with multicentric disease, systemic symptoms may result from circulating IL-6, IL-6 producing B-cells, the generation of excess antibodies or 1,9,10 disseminated HHV-8 infection.
Unicentric-Hyaline Vascular Variant (U-HVV), most common with no predilection for either gender, median age tends to be fourth decade. By definition a single lymph node or chain of lymph nodes is involved. All lymph node groups 3, 4, 11 are involved equally. These patients are often asymptomatic, but can present with compressive symptoms.
Unicentric-Plasma cell Variant (U-PCV), accounts for less than 20% of cases. It is characterized by hypertrophy of and radiotherapy may be a viable option for patients who are poor surgical candidates. A myriad of treatment options exist for patients with MCD. Gancyclovir, interferon-alpha and rituximab may be the best treatment for patients with HHV-8 infection and CD-20 positivity, while CHOP and VAD may be more appropriate for patients with 1 severe systemic manifestations of MCD.
In conclusion, five decades of steady research into the etiology and management of the unusual and fascinating lymphoproliferative disorder has resulted in many answers, but generate a myriad of questions. Innovative treatment strategies have been developed.
In the coming years, however, fundamental questions remain to be answered. Why is CD seen only in small proportion of patients infected with HHV-8? Why do some patients present with localized disease only? What is the role of IL-6 and angiogenesis? What are the best treatment options? 
Clinical categorization (subtypes) and characteristics

Characteristics
